Your fact-checks will appear here
The effectiveness of alpha-lipoic acid in treating diabetic peripheral neuropathy compared to standard pharmacologic therapies.
Randomized trials of (ALA) for diabetic peripheral neuropathy overwhelmingly test ALA versus placebo or vitamins, not versus first‑line symptomatic drugs; intravenous ALA shows short‑term benefit whil...
No high‑quality randomized, head‑to‑head trials directly comparing oral alpha‑lipoic acid (ALA) monotherapy with or for (PDN) have been identified in the provided literature; most randomized trials of...
Clinical trials and meta-analyses most consistently show symptomatic benefit for at about 600 mg of alpha‑lipoic acid (ALA) per day, whether given orally or intravenously, with the strongest randomize...